[go: up one dir, main page]

UA87546C2 - Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof - Google Patents

Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof

Info

Publication number
UA87546C2
UA87546C2 UAA200707837A UAA200707837A UA87546C2 UA 87546 C2 UA87546 C2 UA 87546C2 UA A200707837 A UAA200707837 A UA A200707837A UA A200707837 A UAA200707837 A UA A200707837A UA 87546 C2 UA87546 C2 UA 87546C2
Authority
UA
Ukraine
Prior art keywords
antibiotic
factors
compositions
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
UAA200707837A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Америга Лаззарини
Лучано Гасталдо
Джанпаоло Кандиани
Исмаэла Чичилято
Даниэле Лоси
Флавиа Маринелли
Энрико Селва
Франко Паренти
Original Assignee
Найконс С.К.А.Р.Л
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/035,296 external-priority patent/US7319088B2/en
Application filed by Найконс С.К.А.Р.Л filed Critical Найконс С.К.А.Р.Л
Publication of UA87546C2 publication Critical patent/UA87546C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors Al and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors Al and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.
UAA200707837A 2005-01-12 2005-01-19 Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof UA87546C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/035,296 US7319088B2 (en) 2003-07-18 2005-01-12 Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof

Publications (1)

Publication Number Publication Date
UA87546C2 true UA87546C2 (en) 2009-07-27

Family

ID=38346011

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200707837A UA87546C2 (en) 2005-01-12 2005-01-19 Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof

Country Status (6)

Country Link
KR (1) KR100892655B1 (en)
CY (1) CY1113157T1 (en)
MA (1) MA29144B1 (en)
PT (1) PT1855705E (en)
UA (1) UA87546C2 (en)
ZA (1) ZA200705494B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351687B2 (en) * 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218362B1 (en) * 1997-09-08 2001-04-17 Universite Laval Lantibiotic from Streptococcus mutans and uses thereof

Also Published As

Publication number Publication date
KR20070098903A (en) 2007-10-05
PT1855705E (en) 2012-10-16
KR100892655B1 (en) 2009-04-15
MA29144B1 (en) 2008-01-02
CY1113157T1 (en) 2016-04-13
ZA200705494B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
Trizna et al. Bidirectional alterations in antibiotics susceptibility in Staphylococcus aureus—Pseudomonas aeruginosa dual-species biofilm
Giacometti et al. In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics
TW200510541A (en) Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
Giamarellou et al. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa
WO2006065977A3 (en) Antimicrobial peptides and methods of use
Ghobrial et al. Pharmacodynamic activity of the lantibiotic MU1140
CY1113030T1 (en) ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICAL SALTS AND COMPOSITIONS AND THEIR USE
JP2012513467A5 (en)
Fan et al. Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria
Gómez-Garcés et al. In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria
Giacometti et al. In vitro activity and killing effect of the synthetic hybrid cecropin A–melittin peptide CA (1–7) M (2–9) NH2 on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics
WO2010041970A3 (en) Antibacterial phage peptides and methods of use thereof
Qi et al. Pharmacodynamics of linezolid-plus-fosfomycin against vancomycin-susceptible and-resistant Enterococci in vitro and in vivo of a galleria mellonella larval infection model
Kádár et al. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains
UA87546C2 (en) Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof
Oli et al. Actinomycetes in medical and pharmaceutical industries
Bell et al. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008)
Ulm et al. Targeting bactoprenol-coupled cell envelope precursors
Nastro et al. Antimicrobial activity of Bacillus amyloliquefaciens ANT1 toward pathogenic bacteria and mold: effects on biofilm formation
EA200701267A1 (en) ANTIBIOTIC 107891, ITS A1 AND A2 FACTORS, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS AND THEIR APPLICATION
Williams et al. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
Arhin et al. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters
Sader et al. In vitro activity and potency of the novel oxazolidinone MRX-I tested against contemporary clinical isolates of Gram-positive bacteria
Arooj et al. Texiobactin, a Potent Killer of Antibiotic Resistant Pathogens
Mar Soe et al. Ethyl gallate as a combination drug can overcome resistance in MRSA